The advent of preoperative neoadjuvant therapy, including immune checkpoint inhibitors, as represented by PD-1/PD-L1 inhibitors, has revolutionized ESCC treatment, yet the overall prognosis remains poor. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.